ZDBF2

Summary

ZDBF2 (zinc finger DBF-type containing 2, HGNC:29313) is a protein-coding gene on chromosome 2q33.3, encoding DBF4-type zinc finger-containing protein 2 (Q9HCK1).

This gene encodes a protein containing DBF4-type zinc finger domains. This gene is imprinted and paternally expressed in lymphocytes but is more stochastically expressed in the placenta. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 57683 — RefSeq curated summary.

At a glance

• Gene–disease (curated): nasopalpebral lipoma-coloboma syndrome (Limited, GenCC) — +1 more curated relationship
• GWAS associations: 3
• Clinical variants (ClinVar): 477 total
• MANE Select transcript: NM_020923

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29313
Approved symbol	ZDBF2
Name	zinc finger DBF-type containing 2
Location	2q33.3
Locus type	gene with protein product
Status	Approved
Aliases	FLJ45338, KIAA1571
Ensembl gene	ENSG00000204186
Ensembl biotype	protein_coding
OMIM	617059
Entrez	57683

Gene structure

Transcript identifiers

Ensembl transcripts: 12 — 9 protein_coding, 3 nonsense_mediated_decay

ENST00000374423, ENST00000648361, ENST00000649285, ENST00000649289, ENST00000649441, ENST00000649525, ENST00000649650, ENST00000649998, ENST00000650097, ENST00000920103, ENST00000951868, ENST00000951869

RefSeq mRNA: 3 — MANE Select: NM_020923 NM_001285549, NM_001369654, NM_020923

CCDS: CCDS46501

Canonical transcript exons

ENST00000374423 — 5 exons

Exon	Start	End
ENSE00001463480	206297246	206297373
ENSE00001463481	206281801	206281909
ENSE00001463482	206279540	206279592
ENSE00001463483	206274663	206274946
ENSE00003836421	206304717	206314427

Expression profiles

Bgee: expression breadth ubiquitous, 134 present calls, max score 93.53.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 8.7642 / max 165.9154, expressed in 1350 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
24826	5.6696	1105
24827	2.6219	1030
202547	0.4728	242

Top tissues by expression

134 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
adrenal tissue	UBERON:0018303	93.53	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	84.35	gold quality
corpus callosum	UBERON:0002336	82.28	gold quality
islet of Langerhans	UBERON:0000006	79.63	gold quality
superior frontal gyrus	UBERON:0002661	79.50	gold quality
left ovary	UBERON:0002119	79.33	gold quality
ovary	UBERON:0000992	78.98	gold quality
right hemisphere of cerebellum	UBERON:0014890	78.42	gold quality
cerebellar cortex	UBERON:0002129	78.19	gold quality
cerebellum	UBERON:0002037	78.09	gold quality
cerebellar hemisphere	UBERON:0002245	78.08	gold quality
right ovary	UBERON:0002118	77.93	gold quality
pancreas	UBERON:0001264	77.80	gold quality
pituitary gland	UBERON:0000007	77.75	gold quality
ventricular zone	UBERON:0003053	77.71	gold quality
adenohypophysis	UBERON:0002196	77.64	gold quality
calcaneal tendon	UBERON:0003701	77.45	gold quality
skeletal muscle tissue	UBERON:0001134	77.26	gold quality
body of pancreas	UBERON:0001150	76.90	gold quality
colonic epithelium	UBERON:0000397	76.35	gold quality
stromal cell of endometrium	CL:0002255	76.19	gold quality
nucleus accumbens	UBERON:0001882	75.82	gold quality
adrenal gland	UBERON:0002369	75.34	gold quality
prefrontal cortex	UBERON:0000451	75.32	gold quality
muscle tissue	UBERON:0002385	75.24	gold quality
primary visual cortex	UBERON:0002436	75.09	gold quality
tonsil	UBERON:0002372	75.05	gold quality
bone marrow cell	CL:0002092	74.72	gold quality
ganglionic eminence	UBERON:0004023	74.22	gold quality
smooth muscle tissue	UBERON:0001135	73.94	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.03

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

140 targeting ZDBF2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-1229-3P	99.97	66.49	906
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-23A-3P	99.95	74.24	3163

Literature-anchored findings (GeneRIF, showing 2)

• the human homolog (ZDBF2) of the mouse Zdbf2 gene showed paternal allele-specific expression in human lymphocytes but not in the human placenta. (PMID:19200453)
• Exome sequencing identified a de novo heterozygous frameshift dinucleotide insertion c.6245_6246 insTT (p.His2082fs*67) in ZDBF2 (zinc finger, DBF-type containing 2), a gene located at 2q33.3. This variant was absent in parental DNA, in a set of 300 ethnically matched controls, and in public exome variant databases (PMID:27139419)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Zdbf2	ENSMUSG00000027520
rattus_norvegicus	Zdbf2	ENSRNOG00000024114

Protein

Protein identifiers

DBF4-type zinc finger-containing protein 2 — Q9HCK1 (reviewed: Q9HCK1)

All UniProt accessions (8): A0A3B3IRN6, A0A3B3ISF7, A0A3B3ISJ7, A0A3B3ITR2, A0A3B3ITX6, A0A3B3ITZ5, N0DVB2, Q9HCK1

RefSeq proteins (3): NP_001272478, NP_001356583, NP_065974* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR006572	Znf_DBF	Domain
IPR038545	Znf_DBF_sf	Homologous_superfamily
IPR038890	ZDBF2	Family

Pfam: PF07535

UniProt features (28 total): region of interest 9, compositionally biased region 9, binding site 4, coiled-coil region 2, chain 1, zinc finger region 1, modified residue 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9HCK1-F1	34.79	0.00

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (4): 8; 11; 21; 27

Post-translational modifications (1): 539

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 96 (showing top): GOBP_GENOMIC_IMPRINTING, GOBP_CELLULAR_PROCESS_INVOLVED_IN_REPRODUCTION_IN_MULTICELLULAR_ORGANISM, DODD_NASOPHARYNGEAL_CARCINOMA_UP, GOBP_DEVELOPMENTAL_PROCESS_INVOLVED_IN_REPRODUCTION, GOBP_CHROMATIN_REMODELING, MODULE_95, GOBP_EPIGENETIC_REGULATION_OF_GENE_EXPRESSION, WONG_ADULT_TISSUE_STEM_MODULE, MODULE_163, CBX7_TARGET_GENES, MIR616_5P, MIR371B_5P, MIR373_5P, MIR548AJ_3P_MIR548X_3P, MIR3646

GO Biological Process (1): genomic imprinting (GO:0071514)

GO Molecular Function (3): nucleic acid binding (GO:0003676), zinc ion binding (GO:0008270), metal ion binding (GO:0046872)

GO Cellular Component (0):

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
germ cell development	1
epigenetic programming of gene expression	1
binding	1
transition metal ion binding	1
cation binding	1

Protein interactions and networks

STRING

750 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZDBF2	CMKLR2	P46091	712
ZDBF2	FAM50B	Q9Y247	607
ZDBF2	MCTS2	A0A3B3IRV3	600
ZDBF2	ZNF597	Q96LX8	587
ZDBF2	SNRPN	P14648	578
ZDBF2	RASGRF1	Q13972	571
ZDBF2	ZNF445	P59923	546
ZDBF2	MEST	Q5EB52	525
ZDBF2	DLK1	P15803	520
ZDBF2	PLAGL1	Q9UM63	512
ZDBF2	PEG10	Q86TG7	511
ZDBF2	ZNF331	Q9NQX6	492
ZDBF2	NAP1L5	Q96NT1	482
ZDBF2	ZFP57	Q9NU63	479
ZDBF2	SLC38A4	Q969I6	477

IntAct

45 interactions, top by confidence:

A	B	Type	Score
CSNK1A1	FAM83G	psi-mi:“MI:0914”(association)	0.900
PRPF19	AQR	psi-mi:“MI:0914”(association)	0.790
PRPF19	PLRG1	psi-mi:“MI:0914”(association)	0.770
VAPB	FAM83G	psi-mi:“MI:0914”(association)	0.730
VAPA	FAM83G	psi-mi:“MI:0914”(association)	0.640
PRPF19	STRN	psi-mi:“MI:0914”(association)	0.530
MSH6	PCNA	psi-mi:“MI:0914”(association)	0.530
CPNE2	HIP1	psi-mi:“MI:0914”(association)	0.530
SET	REPIN1	psi-mi:“MI:0914”(association)	0.530
ZDBF2	HSPA5	psi-mi:“MI:0915”(physical association)	0.400
ZDBF2	H1-5	psi-mi:“MI:0915”(physical association)	0.400
ZDBF2	MYH10	psi-mi:“MI:0915”(physical association)	0.400
SENP6	ZDBF2	psi-mi:“MI:0915”(physical association)	0.400
PB2	ESYT2	psi-mi:“MI:0914”(association)	0.350
CSNK1A1	FAM83G	psi-mi:“MI:0914”(association)	0.350
VAPA	FAM83G	psi-mi:“MI:0914”(association)	0.350
SIRT6	HDAC3	psi-mi:“MI:0914”(association)	0.350
CPNE2	SUPT5H	psi-mi:“MI:0914”(association)	0.350
RPL28	SDCBP	psi-mi:“MI:0914”(association)	0.350
SET	HSPA14	psi-mi:“MI:0914”(association)	0.350
SOX2	CBX4	psi-mi:“MI:0914”(association)	0.350
CTBP1	GSN	psi-mi:“MI:0914”(association)	0.350
SOX2	HAX1	psi-mi:“MI:0914”(association)	0.350
PSMB10	DDX46	psi-mi:“MI:0914”(association)	0.350
TAF12	ATL3	psi-mi:“MI:0914”(association)	0.350
SCRIB	CHD2	psi-mi:“MI:0914”(association)	0.350

BioGRID (82): ZDBF2 (Affinity Capture-MS), ZDBF2 (Proximity Label-MS), ZDBF2 (Affinity Capture-MS), ZDBF2 (Affinity Capture-MS), ZDBF2 (Affinity Capture-MS), ZDBF2 (Affinity Capture-MS), ZDBF2 (Affinity Capture-MS), ZDBF2 (Affinity Capture-MS), ZDBF2 (Affinity Capture-MS), ZDBF2 (Affinity Capture-MS), ZDBF2 (Affinity Capture-MS), ZDBF2 (Affinity Capture-RNA), ZDBF2 (Affinity Capture-MS), ZDBF2 (Proximity Label-MS), ZDBF2 (Proximity Label-MS)

ESM2 similar proteins: A0A0P0XCU3, A0A1P8BH59, A1YFC1, A1YGK6, A2T7F2, A6NJ88, B7SY83, F1QU13, F4HXQ7, F4ICX9, F4INW9, F4KCE9, O04251, O81472, O96001, P0CV01, P0CV36, P0CV42, P0CV43, P0CV45, P0CV46, P0CV55, P0CV57, P0CV58, P10322, P16531, P48786, Q0DVU4, Q10P83, Q2EI21, Q3URU2, Q5JY77, Q5QNA6, Q5R7U0, Q5SRN2, Q5U4C1, Q5XPK0, Q6K5K2, Q7T2B3, Q8N3K9

Diamond homologs: Q5SS00, Q9HCK1

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

477 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	333
Likely benign	86
Benign	43

Top pathogenic / likely-pathogenic (0)

SpliceAI

1127 predictions. Top by Δscore:

Variant	Effect	Δscore
2:206274944:GAG:G	donor_gain	1.0000
2:206274945:AGGTG:A	donor_loss	1.0000
2:206274947:G:GG	donor_gain	1.0000
2:206274947:GTGA:G	donor_loss	1.0000
2:206279532:A:G	acceptor_gain	1.0000
2:206279534:TTACA:T	acceptor_loss	1.0000
2:206279536:ACAG:A	acceptor_loss	1.0000
2:206279537:CAGA:C	acceptor_loss	1.0000
2:206279538:A:AG	acceptor_gain	1.0000
2:206279538:AGA:A	acceptor_loss	1.0000
2:206279539:G:GG	acceptor_gain	1.0000
2:206279539:GAT:G	acceptor_gain	1.0000
2:206279539:GATA:G	acceptor_gain	1.0000
2:206279591:AGG:A	donor_loss	1.0000
2:206279593:G:GC	donor_loss	1.0000
2:206279594:T:G	donor_loss	1.0000
2:206281796:TTCA:T	acceptor_loss	1.0000
2:206281797:TCAG:T	acceptor_loss	1.0000
2:206281799:A:AG	acceptor_gain	1.0000
2:206281799:AGCT:A	acceptor_loss	1.0000
2:206281799:AGCTT:A	acceptor_gain	1.0000
2:206281800:G:GA	acceptor_gain	1.0000
2:206281800:GC:G	acceptor_gain	1.0000
2:206281800:GCT:G	acceptor_gain	1.0000
2:206281800:GCTT:G	acceptor_gain	1.0000
2:206281800:GCTTG:G	acceptor_gain	1.0000
2:206281906:ACAGG:A	donor_loss	1.0000
2:206281907:CAGGT:C	donor_loss	1.0000
2:206281908:AGGT:A	donor_loss	1.0000
2:206281909:GGT:G	donor_loss	1.0000

AlphaMissense

15770 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:206297324:T:C	F47L	0.997
2:206297325:T:C	F47S	0.997
2:206297326:C:A	F47L	0.997
2:206297326:C:G	F47L	0.997
2:206281871:T:C	C8R	0.996
2:206281873:C:G	C8W	0.995
2:206281880:T:C	C11R	0.995
2:206281882:C:G	C11W	0.995
2:206310007:T:C	F1827L	0.995
2:206310009:T:A	F1827L	0.995
2:206310009:T:G	F1827L	0.995
2:206310022:T:A	W1832R	0.995
2:206310022:T:C	W1832R	0.995
2:206310076:T:C	F1850L	0.995
2:206310078:T:A	F1850L	0.995
2:206310078:T:G	F1850L	0.995
2:206310014:G:T	G1829V	0.994
2:206310077:T:C	F1850S	0.994
2:206310091:T:C	F1855L	0.994
2:206310093:C:A	F1855L	0.994
2:206310093:C:G	F1855L	0.994
2:206310103:T:C	F1859L	0.994
2:206310105:T:A	F1859L	0.994
2:206310105:T:G	F1859L	0.994
2:206281871:T:A	C8S	0.992
2:206281872:G:C	C8S	0.992
2:206281880:T:A	C11S	0.992
2:206281881:G:A	C11Y	0.992
2:206281881:G:C	C11S	0.992
2:206297248:T:A	H21Q	0.992

dbSNP variants (sampled 300 via entrez): RS1000051241 (2:206281579 C>T), RS1000226743 (2:206287251 G>C), RS1000237744 (2:206280943 A>G), RS1000337650 (2:206298119 G>C), RS1000398242 (2:206293813 C>T), RS1000411190 (2:206294044 A>G), RS1000570800 (2:206304623 A>G), RS1000641989 (2:206299132 C>T), RS1000683400 (2:206287544 A>G), RS1000851945 (2:206276347 C>A,T), RS1000891771 (2:206291288 G>A,C,T), RS1000944421 (2:206285896 A>G,T), RS1000948256 (2:206300183 ACAAAAAC>A), RS1000996968 (2:206286364 A>G), RS1001121790 (2:206279832 C>T)

Disease associations

OMIM: gene MIM:617059 | disease phenotypes: MIM:167730

GenCC curated gene-disease

Disease	Classification	Inheritance
nasopalpebral lipoma-coloboma syndrome	Limited	Autosomal dominant
schizophrenia	No Known Disease Relationship	Unknown

Mondo (3): breast ductal adenocarcinoma (MONDO:0005590), nasopalpebral lipoma-coloboma syndrome (MONDO:0008182), schizophrenia (MONDO:0005090)

Orphanet (1): Nasopalpebral lipoma-coloboma syndrome (Orphanet:2399)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST001567_11	Bipolar disorder and schizophrenia	9.000000e-06
GCST004904_254	Body mass index	6.000000e-09
GCST005951_45	Body mass index	1.000000e-09

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004340	body mass index

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D018270	Carcinoma, Ductal, Breast	C04.557.470.200.025.232.500; C04.557.470.615.132.500; C04.588.180.390; C17.800.090.500.390
C538338	Nasopalpebral lipoma coloboma syndrome (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

37 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, increases expression	4
Air Pollutants	increases oxidation, decreases expression, increases expression, affects cotreatment, increases abundance	3
Particulate Matter	increases abundance, increases expression, decreases expression	3
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
TAK-243	increases sumoylation	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
alpha-pinene	affects cotreatment, increases oxidation, increases abundance	1
pirinixic acid	affects binding, increases activity, increases expression	1
bisphenol A	decreases expression	1
trichostatin A	increases expression	1
sodium arsenite	decreases expression	1
manganese chloride	decreases expression, increases abundance	1
methacrylaldehyde	affects cotreatment, increases oxidation, increases abundance	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	decreases expression	1
entinostat	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	decreases expression, affects cotreatment	1
dorsomorphin	affects cotreatment, decreases expression	1
jinfukang	decreases expression	1
(+)-JQ1 compound	increases expression	1
Acrolein	increases oxidation, increases abundance, affects cotreatment	1
Air Pollutants, Occupational	increases expression	1
Vehicle Emissions	increases abundance, increases expression	1
Benzo(a)pyrene	decreases methylation, increases methylation	1
Doxorubicin	affects expression	1
Lead	affects expression	1
Manganese	decreases expression, increases abundance	1
Methyl Methanesulfonate	increases expression	1
Nickel	increases expression	1

Clinical trials (associated diseases)

311 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00000374	PHASE4	COMPLETED	Treatment for First-Episode Schizophrenia
NCT00001656	PHASE4	COMPLETED	Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders
NCT00007774	PHASE4	COMPLETED	To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia
NCT00014001	PHASE4	COMPLETED	CATIE- Schizophrenia Trial
NCT00018668	PHASE4	COMPLETED	Antipsychotic Response in Schizophrenia
NCT00034801	PHASE4	COMPLETED	Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia
NCT00034905	PHASE4	COMPLETED	A Comparison of Seroquel vs. Risperidone in Schizophrenia
NCT00036088	PHASE4	COMPLETED	Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia
NCT00044187	PHASE4	COMPLETED	The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
NCT00044655	PHASE4	COMPLETED	Switching Medication to Treat Schizophrenia
NCT00048828	PHASE4	COMPLETED	Treating Drug-Resistant Childhood Schizophrenia
NCT00053703	PHASE4	COMPLETED	Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)
NCT00056498	PHASE4	COMPLETED	Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine
NCT00061802	PHASE4	COMPLETED	Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder
NCT00080327	PHASE4	COMPLETED	Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia
NCT00088049	PHASE4	COMPLETED	Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia
NCT00090012	PHASE4	COMPLETED	Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder
NCT00100776	PHASE4	COMPLETED	Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder
NCT00103571	PHASE4	COMPLETED	Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia
NCT00108368	PHASE4	COMPLETED	The Effects of Risperidone and Olanzapine on Thinking
NCT00114595	PHASE4	COMPLETED	Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia
NCT00130923	PHASE4	COMPLETED	Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
NCT00137020	PHASE4	COMPLETED	Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder
NCT00140166	PHASE4	COMPLETED	Treatment of Acute Schizophrenia With Vitamin Therapy
NCT00145847	PHASE4	COMPLETED	Naltrexone Treatment of Alcohol Abuse in Schizophrenia
NCT00148564	PHASE4	COMPLETED	Energy Homeostasis Under Treatment With Atypical Antipsychotics
NCT00156715	PHASE4	COMPLETED	Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder
NCT00158223	PHASE4	COMPLETED	Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia
NCT00159081	PHASE4	COMPLETED	One Year Drug Treatment in First-Episode Schizophrenia
NCT00159120	PHASE4	COMPLETED	Maintenance Treatment vs. Stepwise Drug Discontinuation in First-Episode Schizophrenia
NCT00159133	PHASE4	COMPLETED	Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode Schizophrenia
NCT00159757	PHASE4	TERMINATED	12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients
NCT00167817	PHASE4	COMPLETED	Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study
NCT00169026	PHASE4	TERMINATED	Alcoholism and Schizophrenia: Effects of Clozapine
NCT00169039	PHASE4	TERMINATED	Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia
NCT00169065	PHASE4	COMPLETED	Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia
NCT00169091	PHASE4	TERMINATED	Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia
NCT00176423	PHASE4	COMPLETED	Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia
NCT00176436	PHASE4	COMPLETED	Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients
NCT00177008	PHASE4	COMPLETED	Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety